Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) with IPI-145

Trial Profile

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) with IPI-145

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2014

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2014 New siurce identified and intergrated (ClinicalTrials.gov record; NCT02028039)
    • 23 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top